Welcome to this week's issue of VBC Newsstand brought to you by VBCExhibitHall.com
The Center for Medicare & Medicaid Innovation (CMMI) has launched more than 50 alternative payment and care delivery model tests, with 33 models now or still operational, according to CMMI’s sixth report to Congress on its progress. These model tests have impacted the lives of millions of patients. In the two-year period covering the report, CMMI reports that operational model tests have included over 314,000 healthcare providers and/or plans alone that have impacted the medical care of more than 41.5 million Medicare and Medicaid beneficiaries, as well as commercially-insured individuals. CMMI aims for alternative payment and care delivery model tests to improve the quality of healthcare for these participants while making the delivery of medical care more affordable for all stakeholders.
Artificial intelligence and machine learning are key to unlocking patient data and solving some of healthcare’s most complex problems. Even as the U.S. seeks to put the COVID-19 pandemic in the rearview mirror, many who survive the initial illness suffer debilitating long-term health impacts, especially those with underlying health conditions. Technology allows easier access to disparate data sources without compromising data privacy or integrity. In addition, advanced analytics deliver real-time insights, enabling providers to predict outcomes and diagnose illness early to intervene with patients at risk of developing long-term COVID-19 and other chronic diseases.
Cognitive concerns frequently show up in primary care as adults age, although not all memory loss will progress to the dysfunction of dementia. However, the number of Americans with diagnosed Alzheimer disease (AD) could grow to nearly 14 million by 2060, up from 6.5 million currently. To halt that trend, much of the recent focus has been on the success or failure of drugs to slow the progression of this devastating neurological disease, most notably the FDA’s controversial 2021 approval of aducanumab, a monoclonal antibody, or results of lecanemab, another biologic, which slowed cognitive decline for patients in the early stage of disease but, as with aducanumab, was linked with brain swelling and bleeding. If no viable disease-modifying treatment options appear, the time-starved primary care provider (PCP) will continue to see these patients and families first as AD cases surge in coming decades.
For years we’ve been promised the Emerald City of the U.S. healthcare – a value-based care model. And for good reason. The volume-based fee-for-service care approach we have now is the most expensive in the world and among the worst in quality.
We spend 20% of the country’s GDP on healthcare at an average cost of nearly $12,000 per person annually. That’s roughly double compared to other high-income countries.
Sponsored Webinars

We do not have any upcoming webinar announcements at this time. Keep an eye out for new additions to our schedule here and on our 


Digesting the Alphabet Soup of Medicare’s Final Rule for 2023: APP, MIPS, MVPs, and more!
  • Topic: Learning and understanding key changes for 2023, and receiving insight and guidance on how to adjust and succeed
Sponsored by: Salient Healthcare
December 13, 2022 | 1 PM EST

Technology Trends that Put the Patient First
& Bridge the Interoperability Gap
  • Topic: Exploring the healthcare industry's focus on interoperability, technology trends that focus on bridging the gap, and the benefit of successfully deploying interoperable solutions
Sponsored by: Proficient Health

Check our our Webinar Archive to view past webinars on a variety of value-based care related topics!

Upcoming Conferences
2023 Social Determinants of Health Summit
January 23-24, 2023 | San Diego, CA

2023 Virtual Value-Based Payment Summit: Special Edition
Held in conjunction with Health Care Value Week
January 23-27, 2023 | Virtual

ViVE 2023
March 26-29, 2023 | Nashville, TN

Flash Interview
On occasion, we showcase one of our solution providers in a 4-5 minute interview and ask them what they bring to the VBC Community and what sets them apart. 
Today's guest:
CareSignal, a Lightbeam Company, offers remote monitoring for value-based care organizations. CareSignal Deviceless RPM is accessible, scalable, and cost-effective. CareSignal's standardized, evidence-based SMS text messages and IVR phone calls automatically collect patient-reported outcomes, providing real-time insight into each patient in a large population, and users can receive insights from over two dozen condition-specific programs. CareSignal utilizes evidence-based programs that improve patient engagement and lead to demonstrable financial return.
Platinum Level Exhibitors
Thank you to our Platinum Level exhibitors. These organizations offer the absolute highest quality products & services to the ACO & IPA comty. To learn more & visit their interactive booths, click on the logos below:
Gold Level Exhibitors
Thank you to our Gold Level exhibitors. To learn more & visit their interactive booths, click on the logos below:
Feature your organization here! -- Find out How

Our thoughts and prayers are with the people of Ukraine.